Contrasting Cybin (OTCMKTS:CYBN) and Evolva (OTCMKTS:ELVAF)

Cybin (OTCMKTS:CYBN) and Evolva (OTCMKTS:ELVAF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Earnings and Valuation

This table compares Cybin and Evolva”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	$680,000.00	212.24	-$35.93 million	($4.38)	-1.53
Evolva	N/A	N/A	N/A	C($0.08)	-11.25

Evolva has lower revenue, but higher earnings than Cybin. Evolva is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Cybin and Evolva, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0	0	1	0	3.00
Evolva	0	0	0	0	0.00

Profitability

This table compares Cybin and Evolva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-93.17%	-84.68%
Evolva	N/A	N/A	N/A

Institutional & Insider Ownership

17.9% of Cybin shares are owned by institutional investors. Comparatively, 22.0% of Evolva shares are owned by institutional investors. 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Evolva beats Cybin on 5 of the 9 factors compared between the two stocks.

About Cybin

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

About Evolva

Evolva Holding SA is in the process of liquidation of its remaining assets. Previously, the company was engaged in discovery, research, development, and commercialization of nature-based ingredients for use in flavor and fragrances, health ingredients, health protection, and other sectors in Switzerland, the United States, and internationally. The company was founded in 2004 and is headquartered in Reinach, Switzerland.